Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens

Clinical Cancer Research

Volumn 10, Issue 21, 2004, Pages 7392-7401

  Whitaker, Hayley C ^a   Hanrahan, Sarah ^b   Totty, Nick ^b   Gamble, Simon C ^a   Waxman, Jonathan ^a   Cato, Andrew C B ^c   Hurst, Helen C ^a   Bevan, Charlotte L ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ADENOSINE TRIPHOSPHATE; ALBUMIN; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTIESTROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; CYTOCHALASIN D; CYTOPLASM PROTEIN; FLUTAMIDE; FULVESTRANT; HEAT SHOCK PROTEIN 90; HYDROXYFLUTAMIDE; MANGANESE SUPEROXIDE DISMUTASE; MEMBRANE PROTEIN; MIBOLERONE; NOCODAZOLE; NUCLEAR MATRIX PROTEIN; NUCLEAR PROTEIN; OLIGOMYCIN; TAMOXIFEN; TRANSFERRIN;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CELL FRACTIONATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; HORMONE RESISTANCE; IMMUNOBLOTTING; MASS SPECTROMETRY; MODEL; NONHUMAN; PC3WTAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ADENOSINE TRIPHOSPHATE; ANDROGEN ANTAGONISTS; ANDROGENS; ANILIDES; ANIMALS; CELL LINE, TUMOR; CELL NUCLEUS; COS CELLS; CYTOPLASM; CYTOSKELETON; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FLUTAMIDE; HUMANS; IMMUNOBLOTTING; MALE; MASS SPECTROMETRY; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; PROSTATIC NEOPLASMS; PROTEIN TRANSPORT; RECEPTORS, ANDROGEN; SUBCELLULAR FRACTIONS; TRANSFECTION;

EID: 8544278196     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0388     Document Type: Article

References (43)

1. Crawford ED. Epidemiology of prostate cancer. Urology 2003;62:3-12.
2. Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993;106:1377-88.
3. Guiochon-Mantel A, Lescop P, Christin-Maitre S, et al. Nucleocytoplasmic shuttling of the progesterone receptor. EMBO J 1991;10:3851-9.
4. Hache RJ, Tse R, Reich T, Savory JG, Lefebvre YA. Nucleocytoplasmic trafficking of steroid-free glucocorticoid receptor. J Biol Chem 1999;274:1432-9.
5. Kemppainen JA, Lane MV, Sar M, Wilson EM. Androgen receptor phosphorylation, turnover, nuclear transport and transcriptional activation. J Biol Chem 1992;267:968-74.
6. Jenster G, Trapman J, Brinkmann AO. Nuclear import of the human androgen receptor. Biochem J 1993;293:761-8.
7. Georget V, Lobaccaro JM, Terouanne B, et al. Trafficking of the androgen receptor in living cells with fused green fluorescent protein-androgen receptor. Mol Cell Endocrinol 1997;129:17-26.
8. Waller AS, Sharrard RM, Berthon P, Maitland NJ. AR localisation and turnover in human prostate epithelium treated with the antiandrogen casodex. J Mol Endocrinol 2000;24:339-51.
9. Tyagi RK, Lavrovsky Y, Ahn SC, et al. Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand activated androgen receptor in living cells. Mol Endocrinol 2000;14:1162-74.
10. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 2003;228:111-33.
11. Warriar N, Page N, Koutsilieris M, Govindan MV. Interaction of antiandrogen-androgen receptor complexes with DNA and transcription activation. J Steroid Biochem Mol Biol 1993;46:699-711.
12. Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 2002;277:26321-6.
13. Veldscholte J, Berrevoets CA, Ris-Stalpers C, et al. The androgen receptor in LNCaP cells contains a mutation in the ligand-binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 1992;41:665-9.
14. Peterziel H, Mink S, Schonert A, et al. Rapid signalling by androgen receptor in prostate cancer cells. Oncogene 1999;18:6322-9.
15. Ray DW, Davis JRE, A W, Clark AJL. Glucocorticoid receptor structure and function in glucocorticoid-resistant small cell lung carcinoma cells. Cancer Res 1996;56:3276-80.
16. Staufenbiel M, Deppert W. Preparation of nuclear matrices from cultured cells: subfractionation of nuclei in situ. J Cell Biol 1984;98:1886-94.
17. Trapman J, Klaasen P, Kuiper GGJM, et al. Cloning, structure and expression of a cDNA encoding the human androgen receptor. Biochem Biophys Res Commun 1988;153:241-8.
18. Gamble SC, Odontiadis M, Waxman J, et al. Androgens target prohibitin to regulate proliferation of prostate cancer cells. Oncogene 2004;23:2996-3004.
19. Jindal S, Dudani A, Singh B, Harley C, Gupta R. Primary structure of a human mitochondrial protein homologous to the bacterial and plant chaperonins and to the 65-kilodalton mycobacterial antigen. Mol Cell Biol 1989;9:2279-83.
20. Tong WM, Cortes U, Wang ZQ. Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis. Biochim Biophys Acta 2001;1552:27-37.
21. Goldman RD, Gruenbaum Y, Moir RD, Shumaker DK, Spann TP. Nuclear lamins: building blocks of nuclear architecture. Genes Dev 2002;16:533-47.
22. MacGillivray RT, Mendez E, Sinha SK, et al. The complete amino acid sequence of human serum transferrin. Proc Natl Acad Sci USA 1982;79:2504-8.
23. 2+-binding activity. Biochim Biophys Acta 1998;1386:121-31.
24. Kato H, Fukuda T, Parkison C, McPhie P, Cheng SY. Cytosolic thyroid hormone-binding protein is a monomer of pyruvate kinase. Proc Natl Acad Sci USA 1989;86:7861-5.
25. Lopez-Fanarraga M, Avila J, Guasch A, Coll M, Zabala JC. Review: postchaperonin tubulin folding cofactors and their role in microtubule dynamics. J Struct Biol 2001;135:219-29.
26. Ting J, Lee AS. Human gene encoding the 78,000-dalton glucose-regulated protein and its pseudogene: structure, conservation, and regulation. DNA 1988;7:275-86.
27. Shav-Tal Y, Zipori D. PSF and p54(nrb)/NonO: multi-functional nuclear proteins. FEBS Lett 2002;531:109-14.
28. Ginisty H, Sicard H, Roger B, Bouvet P. Structure and functions of nucleolin. J Cell Sci 1999;112:761-72.
29. Gunning P, Ponte P, Okayama H, et al. Isolation and characterization of full-length cDNA clones for human alpha-, beta-, and gamma- actin mRNAs: skeletal but not cytoplasmic actins have an amino-terminal cysteine that is subsequently removed. Mol Cell Biol 1983;3:787-95.
30. Iwasaki T, Murata-Hori M, Ishitobi S, Hosoya H. Diphosphorylated MRLC is required for organization of stress fibers in interphase cells and the contractile ring in dividing cells. Cell Struct Funct 2001;26:677-83.
31. Sundstrom BE, Stigbrand TI. Cytokeratins and tissue polypeptide antigen. Im J Biol Markers 1994;9:102-8.
32. Helfand BT, Chang L, Goldman RD. Intermediate filaments are dynamic and motile elements of cellular architecture. J Cell Sci 2004;117:133-41.
33. Holzmann K, Korosec T, Gerner C, Grimm R, Sauermann G. Identification of human common nuclear-matrix proteins as heterogeneous nuclear ribonucleoproteins H and H′ by sequencing and mass spectrometry. Eur J Biochem 1997;244:479-86.
34. Ho YS, Crapo JD. Isolation and characterization of complementary DNAs encoding human manganese-containing superoxide dismutase. FEBS Lett 1988;229:256-60.
35. Meloun B, Moravek L, Kostka V. Complete amino acid sequence of human serum albumin. FEBS Lett 1975;58:134-7.
36. Ozanne DM, Brady ME, Cook S, et al. Androgen receptor nuclear translocation is facilitated by f-actin cross-linking protein filamin. Mol Endocrinol 2000;14:1618-26.
37. Tang Y, DeFranco DB. ATP-dependent release of glucocorticoid receptors from the nuclear matrix. Mol Cell Biol 1996;16:1989-2001.
38. Dotzlaw H, Moehren U, Mink S, et al. The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol Endocrinol 2002;16:661-73.
39. Taplin ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 2004;91:483-90.
40. Peterziel H, Culig Z, Stober J, et al. Mutant androgen receptors in prostatic tumours distinguish between amino-acid-sequence requirements for transactivation and ligand binding. Int J Cancer 1995;63:544-50.
41. Hara T, Miyazaki J, Araki H, et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003;63:149-53.
42. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
43. Morris C, Wakeling A. Fulvestrant ("Faslodex"): a new treatment option for patients progressing on prior endocrine therapy. Endocr Relat Cancer 2002;9:267-76.